DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. (December 2016) - Janku, F.; George, S.; Razak, A.; Gordon, M.; Brooks, D.; Flynn, D.G.; Kaufman, M.; Pitman, J.; Smith, B.; Somaiah, N.; Gerstenberger, E.; Westwood, D.; et al.